This multicenter study evaluated the efficacy and safety of cycloserine and measured its effects on explicit and implicit memory tests in patients with Alzheimer's disease (AD). Four hundred ten patients with AD, aged 50 years or older, were enrolled in this parallel-group, double-blind, placebo-controlled, randomized trial of 5,15, or 50 mg cycloserine or placebo twice daily, and 403 entered the double-blind treatment phase. Two hundred sixty-five patients completed the entire 26-week treatment phase. There were no baseline differences among the four treatment groups. Cognitive Drug Research (CDR) efficacy assessments showed no differences between active treatments and placebo from baseline to study weeks 2, 6, 14, or 26. Patients receiving 15 mg of cycloserine improved significantly on one section of an implicit memory test. No differences among treatments were observed for any other assessment scales evaluated. The incidence and severity of adverse events were similar across treatment groups. Cycloserine was well tolerated but did not demonstrate consistent evidence of efficacy during the course of therapy. Higher doses may be necessary to achieve efficacy in the AD population and do not appear to be precluded by the adverse event profile seen in this study.
Get full access to this article
View all access options for this article.
References
1.
1. Gottfries CG. Alzheimer's diseases and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology (Berl)1985; 86:245–252.
2.
2. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory. Science1985; 217:408–417.
3.
3. Zornetzer SF. The noradrenergic locus coeruleus and senescent memory dysfunction. In: Croos T, Bartus RT, Ferris SH, Gershon S, Eds. Treatment Development Strategies for Alzheimer's Disease. Madison, CT: Mark Powley Associates, 1986: 337–360.
4.
4. Samorajski T.Central neurotransmitter substances and aging: a review. J Am Geriatr Soc1977; 25:337–348.
5.
5. Antola A, Singer W.Long term potentiation and NMDA receptors in rat visual cortex. Nature1987; 330:649–652.
6.
6. Colingridge GL, Bliss TVP. NMDA receptors — their role in long-term potentiation. Trends Neurosci1987; 10:288–293.
7.
7. Morris RGM, Anderson E, Lynch GS, Baudry M.Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist AP-5. Nature1986; 319:774–776.
8.
8. Nair KGS, Epstein IG, Baron H, Mulinos MG. Absorption, distribution and excretion of cycloserine in man. In: Antibiotics Annual. New York: Med. Encyclopedia Inc, 1955-56: 169–172.
9.
9. Watson GB, Bolanowski MA, Baganoff MP, et al. D-cycIoserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in xenopus oocytes. Brain Res1990; 510:158–160.
11. Monahan JB, Handelmann GE, Hood WF, Cordi AA. D-cycloserine, a positive modulator of the N-methyl-d-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav1989; 34:649–653.
12.
12. Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett1989; 98:91–95.
13.
13. Wood PL, Emmett MR, Rao TS, et al. In vivo modulation of the N-methyl-d-aspartate receptor complex by D-serine: potentiation of ongoing neuronal activity as evidenced by increased cerebellar cyclic GMP. J Neurochem1989; 53:979–981.
14.
14. Appollonio I, Grafman J, Clark K, et al. Implicit and explicit memory in patients with Parkinson's disease with and without dementia. Arch Neurol1994; 51:359–367.
15.
15. Folstein MR, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12:189–198.
18. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol1980; 7:486–488.
19.
19. Hamilton M.Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol1967; 6:278–296.
20.
20. Wesnes K, Simpson P, White L, Pinker S.The cognitive drug research computerized assessment systems for elderly, AAMI and demented patients. J Psychopharmacol1992; 6: 108.
22. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: U.S. Department of Health, Education and Welfare Pub. No. (ADM) 76-338, NIMH, 1976.
23.
23. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist1969; 9:179–186. (Modified by adding Items I and J written by Croos TH, and Raskin A, Psychopharmacology Branch, NIMH).
24.
24. Holm SA. A simple sequentially rejective multiple test procedure. Scand J Stat1979; 6:65–90.
25.
25. Knopman DS, Nissen MJ. Implicit learning in patients with probable Alzheimer's disease. Neurology1987; 37:784–788.
26.
26. Keane MM, Gabrieli JD, Fennema AC, et al. Evidence for a dissociation between perceptual and conceptual priming in Alzheimer's disease. Behav Neurosci1991; 105:326–342.
27.
27. Butters N, Heindel WC, Salmon DP. Dissociation of implicit memory in dementia: neurological implications. Bull Psychonomic Soc1990; 28:359–366.
28.
28. Quartermain D, Mower J, Rafferty MF, et al. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol1994; 257:7–12.
29.
29. Cutler NR, Sramek JJ, Murphy MF, et al. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's Disease. Ann Pharmacother1992; 26:1118–1122.
30.
30. Cutler NR, Sramek JJ, Seifert RD, et al. The target population in Phase I clinical trials of acetylcholinesterase inhibitors in dementia: the role of the “Bridging Study.”Alzheimer's Dis Adv Clin Basic Res1993; 64:560–562.
31.
31. Cutler NR, Sramek JJ, Murphy MF, et al. Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's Disease. J Geriatr Psychiatry Neurol1992; 5:192–194. Editorial.
32.
32. Cutler NR, Sramek JJ. Tacrine in Alzheimer's disease. N Engl J Med1993; 328:808. Letter.
33.
33. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's Disease. JAMA1994; 271:985–991.
34.
34. Cutler NR, Fakouhi TD, Smith WT, et al. Evaluation of multiple doses of milacemide in the treatment of Senile Dementia of the Alzheimer's type. J Geriatr Psychiatry Neurol1993; 6:115–119.
